MCM
CGTX icon

MAI Capital Management’s Cognition Therapeutics CGTX Stock Holding History

MAI Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250
Closed -$190 – 2535
2026
Q1 		$190 Hold
250
– – ﹤0.01% 4635
2025
Q4 		$338 Hold
250
– – ﹤0.01% 3938
2025
Q3 		$338 Buy
250
+50
+25% +$68 ﹤0.01% 3661
2025
Q2 		$62 Hold
200
– – ﹤0.01% 3910
2025
Q1 		$85 Hold
200
– – ﹤0.01% 3369
2024
Q4 		$141 Buy
+200
New +$99 ﹤0.01% 3405

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

MAI Capital Management's CGTX Position: Q2 2026 in Review

MAI Capital Management sold out of Cognition Therapeutics (CGTX) in Q2 2026, closing a stake of 250 shares — an estimated $190 sold.

MAI Capital Management first reported a position in CGTX in Q4 2024 and held it in 6 quarters. The position peaked at $338 in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • MAI Capital Management reported no remaining Cognition Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 250 Cognition Therapeutics shares in Q2 2026, an estimated $190.
  • MAI Capital Management first reported a position in Cognition Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Cognition Therapeutics position peaked at $338 in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.